Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2012

View Archived Issues

Novel inhibitors of GlyT1 designed in Japan

Roche reviews developments of first quarter 2012

Eisai divulges new suppressors of prostanoid signaling

Collaboration yields novel potential therapies for hepatitis C

Investigators in U.S. link desaturase to survival of patients with breast cancer

Potential new antidepressant has promising pharmacokinetic profile

Novel microRNA-based drug shows potential to treat liver cancer

Potent ROCK inhibitors with oncolytic potential identified in U.S.

Novel antimalarials identified through phenotypic whole-cell screening

New P2X7 receptor antagonists patented by Merck & Co.

Takeda and Metabolon to collaborate on targets/biomarkers

Rockland Immunochemicals and LIMR enter commercialization agreement

Five Prime Therapeutics and GSK collaborate on respiratory diseases

Michael J. Fox Foundation funds to-BBB Parkinson's disease research

Sucampo and Clinigen implement named-patient program for Amitiza

ME-3738 program discontinued

Celek Pharmaceuticals provides update on progress for CEL-031

Eisai presents PARP inhibitor with promising anticancer activity

Argyle Therapeutics out-licenses topical rosacea treatment candidate

Tengion plans IND submission for Neo-Kidney Augment

Pluristem receives clearance for phase II PLX-PAD trial

FDA issues complete response letter for Pliaglis sNDA

MSD launches antifungal drug in Japan

BMS and Janssen expand collaboration on TMC-435 and BMS-790052

Bayer Yakuhin launches anticoagulant tablet in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...